(117) demonstrate that serum exosomal miR-150 decreased after low-dose rituximab (RTX) treatment in patients with anti-AChR antibodies positive refractory MG, and alleviated symptoms of MG, these results suggest that the relationship may be related to miR-150 interactions with CD19+ and CD27+ B cells. The gene discussed is CD19; the disease is myasthenia gravis.